Results 21 to 30 of about 40,867 (262)

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Frontiers in Oncology, 2020
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of ...
Hengyuan Li, Hengyuan Li, Junjie Gao, Junjie Gao, Youshui Gao, Nong Lin, Minghao Zheng, Zhaoming Ye   +7 more
doaj   +1 more source

Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study

Bone Reports, 2021
Purpose: Denosumab reduces bone resorption and improves bone mineral density (BMD). Studies have analyzed subsequent treatment transitioning from bisphosphonates to denosumab based on dual-energy X-ray absorptiometry scanning (DXA). Quantitative computed
Koki Tsuchiya, Koji Ishikawa, Yoshifumi Kudo, Soji Tani, Takashi Nagai, Tomoaki Toyone, Katsunori Inagaki   +6 more
doaj   +1 more source

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

JCI Insight, 2023
Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear.
Q. Fu, N. C. Bustamante-Gomez, Humberto Reyes-Pardo, I. Gubrij, D. Escalona-Vargas, J. Thostenson, M. Palmieri, Joseph J. Goellner, I. Nookaew, C. Barnes, J.B. Stambough, E. Ambrogini, Charles A. O’Brien   +12 more
semanticscholar   +1 more source

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan

Osteoporosis International, 2023
In this multi-institutional retrospective cohort study, we compared the long-term risk of osteonecrosis of the jaw following the use of denosumab vs. bisphosphonates in osteoporotic patients.
Fang-Chun Liu, K. Luk, Yung-Chih Chen
semanticscholar   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Long-Term Effect of Denosumab on Bone Disease in Patients with CKD

American Society of Nephrology. Clinical Journal, 2023
Visual Abstract Background The effect of long-term denosumab therapy and of denosumab discontinuation on the cortical bone of the hip regions in dialysis patients has not been studied.
Ken Iseri, Masahide Mizobuchi, R. Winzenrieth, L. Humbert, T. Saitou, Tadashi Kato, Yutaka Nakajima, Mikio Wakasa, K. Shishido, H. Honda   +9 more
semanticscholar   +1 more source

Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. [PDF]

, 2019
Denosumab has been used successfully to treat disease-associated osteoclast overactivity, including giant cell tumor of bone. Given its mechanism of action, denosumab is a potent potential treatment of other osteoclast bone dysplasias including central ...
Bernthal, Nicholas M, Bukata, Susan, Eilber, Fritz C, Federman, Noah C, Felsenfeld, Alan L, Nelson, Scott D, Singh, Arun, Upfill-Brown, Alexander, Wesseling-Perry, Katherine   +8 more
core   +2 more sources

Positioning novel biologicals in CKD-mineral and bone disorders [PDF]

, 2017
Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian, Mazzaferro, Sandro, Muci, MARIA LUISA, Pasquali, Marzia, Rotondi, Silverio, Tartaglione, Lida   +5 more
core   +1 more source

Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population‐Based Cohort Study

Journal of Bone and Mineral Research, 2023
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. The incidence of and risk factors for hypocalcemia after denosumab use are not well established. Using linked health care databases
A. Cowan, N. Jeyakumar, E. McArthur, J. Fleet, T. Kanagalingam, I. Karp, Tayyab S. Khan, F. Muanda, D. Nash, S. Silver, J. Thain, M. Weir, A. Garg, K. Clemens   +13 more
semanticscholar   +1 more source